REPL

Replimune Group, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1737953Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2026

—

Net Income FY2026

$(314.0M)

EPS (Basic, as reported)

$-3.38

Net Margin FY2026

—

ROE FY2026

-188.9%

Total Equity

$166.0M

Shares Out

94M

Business description

Replimune Group, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2017–FY2026; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (8) → (314)

Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026

Research & development(7)(14)(22)(39)(57)(80)(127)(175)(189)(221)

Selling, general & administrative————————(72)(99)

General & administrative(3)(6)(9)(17)(23)(39)(51)(60)(72)—

Total operating expenses(10)(19)(31)(56)(80)(118)(177)(235)(262)(320)

Operating income(10)(19)(31)(56)(80)(118)(177)(235)(262)(320)

Interest expense———(1)(1)0(2)(4)(6)(7)

Interest & investment income00321010232114

Other income (expense), net2004(1)0319155

Pre-tax income(8)(20)(31)(53)(81)(118)(174)(215)(247)(314)

Income tax expense000000000(1)

Net income(8)(20)(31)(53)(81)(118)(174)(216)(247)(314)

EPS — basic————($1.75)($2.26)($2.99)($3.24)($3.07)($3.38)

EPS — diluted————($1.75)($2.26)($2.99)($3.24)($3.07)($3.38)

Shares outstanding — basic (M)————465258678193

Shares outstanding — diluted (M)————465258678193

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.